Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc.
- Market cap
- $7.62M
Your view on ALGS
Overview
What the company does, where it operates, and who runs it.
About Aligos Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Lawrence M. Blatt MBA,
- Headquarters
- One Corporate Drive, South San Francisco, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Lawrence M. Blatt MBA,
- Headquarters
- One Corporate Drive, South San Francisco, CA, US
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.
Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.
The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH).
In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells.
It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH.
The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Aligos Therapeutics, Inc.. Starting points for Aligos Therapeutics, Inc.: EPS -$6.34, beta 2.42 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Aligos Therapeutics, Inc.. Trailing twelve-month EPS for Aligos Therapeutics, Inc. stands at -$6.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Aligos Therapeutics, Inc.. Aligos Therapeutics, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| CYTKCytokinetics, Incorporated | Healthcare | NASDAQ | $7.1B | ||
| BXRXQBaudax Bio, Inc. | Healthcare | OTC | $436 | ||
| BYSIBeyondSpring Inc. | Healthcare | NASDAQ | $13.7M | ||
| CABACabaletta Bio, Inc. | Healthcare | NASDAQ | $201.9M | ||
| CADLCandel Therapeutics, Inc. | Healthcare | NASDAQ | $395.4M | ||
| CAICaris Life Sciences, Inc. | Healthcare | NASDAQ | $5.0B | ||
| CAIHFChia Tai Enterprises International Limited | Healthcare | OTC | $217.4M | ||
| CALACalithera Biosciences, Inc. | Healthcare | OTC | $974 | ||
| CALCCalciMedica, Inc. | Healthcare | NASDAQ | $4.0M | ||
| CAMPCAMP4 Therapeutics Corporation | Healthcare | NASDAQ | $237.8M | ||
| CAMRFCamurus AB (publ) | Healthcare | OTC | $3.5B | ||
| CANFCan-Fite BioPharma Ltd. | Healthcare | AMEX | $1.9M | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Aligos Therapeutics, Inc., and how their positions are changing. At a $7.6M market value, institutional positions materially move Aligos Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Aligos Therapeutics, Inc. executives and directors. Shares of Aligos Therapeutics, Inc. have traded between $3.76 and $46.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Aligos Therapeutics, Inc.. Coverage tracks Aligos Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Aligos Therapeutics, Inc.